Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Eisai Hands Over Fosravuconazole Rights in Asia/Oceania to Sato
Eisai said on July 16 that it has inked a licensing pact with Sato Pharmaceutical regarding the development and commercialization rights to its antifungal agent fosravuconazole for the treatment of fungal diseases in Asia and Oceania. Based on the deal,…
To read the full story
Related Article
- Sato, Eisai to Wind Up Collab on Antifungal Nailin
March 5, 2025
BUSINESS
- AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
- AstraZeneca Sees Broad Pipeline, AI Powering 50-Plus Approval Goal
August 5, 2026
- Rohto Takes Control of OPBio to Bolster Marine Biotech R&D
August 5, 2026
- Specialist Hails Zepbound’s OSA Nod as Major Treatment Advance
August 5, 2026
- Gotham Questions Sumitomo Accounting; Company Rejects Claims
August 5, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…